Cancer Diagnostics Company - Pre-IPO Existing Shareholding - FDA Listed ISO13485 Certified
| Categories: | Securities, Pre-IPO / Grey Market |
| Sale Type: | Asking Price |
| Price Guide: | AUD 6M shares @ $0.14 per share (cum rights) = 24.32% discount to December 2016 Pre-IPO Rights Issue |
| Status: | Closed |
Summary:
Sale of pre-IPO existing shares by a motivated Seller in a public, unlisted Company based in Melbourne, Australia. Since 2007, the Company has successfully realised IP value in telomerase-based diagnostics to effectively identify bladder cancer. In 2016 it transitioned from a purely R&D company to a commercial entity with product revenues. Has recently formalised distribution agreements for US and UK markets. Since inception, the Company has raised A$16.1M in equity to successfully achieve milestones and has been well supported by considerable R&D Incentives.
Share this Listing
Arbortech
BlackWall
Blooms the Chemist
Genex Power
Haoma Mining
Moneytech
Planet Innovation Holdings
PrimaryMarkets
VGW Holdings
Waratah Hotel Group
XYZ Ltd
Capital Raises
Secondary Trading
